<DOC>
	<DOC>NCT02547441</DOC>
	<brief_summary>This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>1. Healthy, male and nonpregnant female subjects, 18 years of age or older. 2. A diagnosis of papulopustular rosacea with â‰¥30 inflammatory facial lesions at Baseline. Subjects must have no more than 2 nodular lesions, at Baseline. 3. Subjects with the presence of telangiectasia at Baseline. 4. Subjects with an erythema score of at least 2 on the Investigator Assessment of Erythema scale at Baseline. 5. Subjects with severe rosacea on the Investigators Global Assessment scale at Baseline. 1. Subjects with steroid rosacea or subtype 3 (phymatous rosacea). 2. Subjects with nodular rosacea. 3. Standard exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>